Cannella M, Simonelli M, D'Alessio C, Pierelli F, Ruggieri S, Squitieri F
Department of Molecular Pathology, IRCCS INM Neuromed, Pozzilli, Italy.
Neurol Sci. 2001 Feb;22(1):55-6. doi: 10.1007/s100720170044.
Huntington's disease (HD) and dominant ataxias (SCA) represent neurodegenerative hereditary diseases dominantly transmitted for which a direct and accurate genetic test is now available for molecular confirmation and presymptomatic test. Predictive testing programs, according to published international guidelines, are available worldwide. A large number of subjects (n=165) required a predictive HD diagnosis, although only 36% completed the program flow-chart and received the final genetic result (26 had a positive, 34 negative result for mutation). In 4 cases, an allele of intermediate range (33-34 CAGs) was found. Two of these shared the intermediate allele with an expanded repeat. In this case, we estimated the patient's risk to have affected children over the usually reported 50%. In 4 cases, the presymptomatic diagnosis was requested by persons at-risk for SCA1 and SCA3/Machado-Joseph disease. There were no adverse events to results of both HD and SCA presymptomatic diagnoses.
亨廷顿舞蹈病(HD)和显性共济失调(SCA)是主要通过遗传方式传播的神经退行性疾病,目前可通过直接且准确的基因检测进行分子确诊和症状前检测。根据已发布的国际指南,预测性检测项目在全球范围内均可开展。大量受试者(n = 165)需要进行HD预测性诊断,尽管只有36%的受试者完成了项目流程并获得了最终基因检测结果(26例突变结果为阳性,34例为阴性)。在4例中,发现了中等范围等位基因(33 - 34个CAG)。其中2例与一个扩增重复序列共享中等等位基因。在此情况下,我们估计患者生育患病子女的风险高于通常报道的50%。有4例中,SCA1和SCA3/马查多 - 约瑟夫病的高危人群要求进行症状前诊断。HD和SCA症状前诊断结果均未出现不良事件。